Spectral Med Inc experienced a notable uptick in its stock price, reflecting investor optimism.
In yesterday's trading session, Spectral Med Inc (EDT.TO) saw its stock price increase by 2.22%, closing at CA$1.38. This positive movement comes amid ongoing developments in the company's product pipeline, particularly concerning its PMX application.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$404.92M
52W high
$1.76
52W low
$0.80
1W change
+0.73%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 128.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+128.3% Upside
Current Price
C$1.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
25.5%
Annualized
90-Day Vol
34.7%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$1.38
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 โ C$1.51 |
| 60 trading days | C$1.38 | C$1.22 โ C$1.56 |
| 90 trading days | C$1.38 | C$1.18 โ C$1.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may view the recent uptick in Spectral Med's stock as a signal of growing confidence in the company's future prospects, especially with its recent FDA filing.
Spectral Med Inc Market Cap Reaches CA$404.9 Million
With a market cap of CA$404.9 million, Spectral Med Inc is positioned within the small-cap segment, which often entails higher volatility and risk.
Bull case
The recent submission of the PMA application for PMX to the U.S. FDA could boost investor sentiment. If the FDA approves the application, it might open up significant market opportunities and lead to revenue growth for the company.
Bear case
Despite the positive movement, the company still faces challenges typical of small-cap biotech firms. These include regulatory hurdles and the ongoing need to successfully commercialize its products.
Recent Developments
The increase in Spectral Med's stock price coincided with the company's recent submission of a Premarket Approval (PMA) application for PMX to the U.S. FDA. This significant step could pave the way for future revenue streams if the product gains approval.
Market Sentiment
Investor sentiment appears to be shifting positively, as evidenced by the stock's performance. The market's reaction suggests that stakeholders are optimistic about the potential outcomes of the FDA review process, which could lead to increased demand for PMX.
Looking Ahead
As Spectral Med Inc continues to navigate the complexities of the biotech landscape, investors will be watching closely for further developments regarding the PMA application and any additional clinical trial results that could impact the company's trajectory.
Advertisement
